Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $225.00 Price Target at Leerink Partners

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective increased by Leerink Partners from $215.00 to $225.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently commented on the stock. Raymond James Financial started coverage on shares of Jazz Pharmaceuticals in a report on Friday, April 10th. They issued an “outperform” rating and a $227.00 price objective for the company. Needham & Company LLC lifted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Truist Financial raised shares of Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $216.87.

Jazz Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:JAZZ opened at $202.40 on Wednesday. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The company has a fifty day simple moving average of $185.67 and a 200 day simple moving average of $168.17. The firm has a market cap of $12.46 billion, a PE ratio of -33.90, a price-to-earnings-growth ratio of 0.35 and a beta of 0.23. Jazz Pharmaceuticals has a 12-month low of $97.50 and a 12-month high of $207.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.51 earnings per share. On average, equities research analysts anticipate that Jazz Pharmaceuticals will post 20.65 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the transaction, the director owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 55,600 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the transaction, the executive vice president directly owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. This trade represents a 49.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 74,015 shares of company stock valued at $14,180,486. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Hilltop National Bank acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $36,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $38,000. Farther Finance Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the period. Leonteq Securities AG acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $50,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $51,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.